Cargando…
Phase 0 - Microdosing strategy in clinical trials
Drug development is an activity that is long, complex and expensive. In 2004, attrition in the drug development paradigm prompted the US Food and Drug Administration (FDA) to introduce its ‘Critical Path’ document, which highlighted the serious discordance between major scientific advances and limit...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025138/ https://www.ncbi.nlm.nih.gov/pubmed/21279177 http://dx.doi.org/10.4103/0253-7613.45147 |